Quantitative Comparison of Presenilin Protein Expression Reveals Greater Activity of PS2-gamma-Secretase.

Abstract

{gamma}-Secretase processing of APP has long been of interest in the pathological progression of Alzheimers disease (AD) due to its role in the generation of amyloid-{beta}. The catalytic component of the enzyme are the presenilins of which there are two homologues, Presenilin-1 (PS1) and Presenilin-2 (PS2). The field has focussed on the PS1 form of this enzyme, as it is typically considered the more active at APP processing. However, much of this work has been completed without appropriate consideration of the specific levels of protein expression of PS1 and PS2. We propose that expression is an important factor in PS1- and PS2-{gamma}-secretase activity, and that when this is considered, PS1 does not have greater activity than PS2. We developed and validated tools for quantitative assessment of PS1 and PS2 protein expression levels to enable direct comparison of PS protein in exogenous and endogenous expression systems, in HEK-293 PS1 and/or PS2 knockout cells. We show that exogenous expression of Myc-PS1-NTF is 5.5-times higher than and Myc-PS2-NTF. Quantitating endogenous PS protein levels using a novel PS1/2 fusion standard we developed showed similar results. When the marked difference in PS1 and PS2 protein levels is considered, we show that compared to PS1-{gamma}-secretase, PS2-{gamma}-secretase has equal or more activity on APP and Notch1. This study has implications for understanding the PS1 and PS2 specific contributions to substrate processing, and their potential influence in AD pathogenesis.